Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANSOTO: Sotorasib + Chemotherapy in Advanced Pancreatic Adenocarcinoma
NCT06892054Phase 1Recruiting
- Sponsor
- Spanish Cooperative Group for Digestive Tumour Therapy
- Start
- Aug 2025
- Primary completion
- Aug 2030
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of sotorasib in pancreatic adenocarcinoma (PDAC), sponsored by Spanish Cooperative Group for Digestive Tumour Therapy. Primary endpoint: Safety and Tolerability at 60 months. Started Aug 2025; status: recruiting.
02
Drugs
sotorasib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06892054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06892054.